Answers are grounded in this paper and cite their sources.
This commentary discusses regulatory challenges in AI-enabled multi-omics technologies, indicating implications for clinical adoption.
The convergence of (multi-)omics and artificial intelligence is transforming precision medicine by enabling data-driven diagnostics, treatment prediction, and patient stratification. Yet, regulatory frameworks lag behind this innovation. This commentary discusses emerging issues around data integrity, algorithm transparency, validation and real-world evidence integration, highlighting gaps between device and pharmaceutical regulations. Drawing on examples of regulatory-approved AI-enabled (multi-)omics tools in the EU and US, we explore evolving regulatory pathways shaping the clinical adoption of next-generation tools for precision medicine.
No takes yet. Share an insight, caveat, or question.
Welzel et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: